ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptotic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.

Related Animations

THE ROLE OF SEROTONIN IN CARCINOID SYNDROME

THE ROLE OF SEROTONIN IN CARCINOID SYNDROME

View
FROM MELANOCYTE TO MELANOMA

FROM MELANOCYTE TO MELANOMA

View
NANOT BIOANIMATION 2020

NANOT BIOANIMATION 2020

View